Substance / Medication

Cefepime

Overview

Active Ingredient
cefepime
RxNorm CUI
20481

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

8 trials linked to this intervention

8
Total Trials
1
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Unveiling predisposing factors for cefepime-induced neurotoxicity: A systematic review and meta-analysis.
Hardi Harri, Louisa Melva, Widyahening Indah Suci et al. · Br J Clin Pharmacol · 2025
PMID: 40523836Meta-Analysis
Resistance of Gram-Negative Bacteria to Cefepime-Enmetazobactam: A Systematic Review.
Falagas Matthew E, Romanos Laura T, Kontogiannis Dimitrios S et al. · Pathogens · 2025
PMID: 40872287Meta-AnalysisFull text (PMC)
Cefepime-induced neurotoxicity: systematic review.
Maan Gozun, Keitoku Koichi, Kimura Nobuhiko et al. · J Antimicrob Chemother · 2022
PMID: 35971666Meta-Analysis
Cefepime-induced neurotoxicity: a systematic review.
Payne Lauren E, Gagnon David J, Riker Richard R et al. · Crit Care · 2017
PMID: 29137682Meta-AnalysisFull text (PMC)
Evaluating outcomes of alternative dosing strategies for cefepime: a qualitative systematic review.
Burgess Sarah V, Mabasa Vincent H, Chow Ivy et al. · Ann Pharmacother · 2015
PMID: 25575975Meta-Analysis
Meta-analysis of a possible signal of increased mortality associated with cefepime use.
Kim Peter W, Wu Yu-te, Cooper Charles et al. · Clin Infect Dis · 2010
PMID: 20624065Meta-Analysis
Meta-analysis of a possible signal of increased mortality associated with cefepime use.
Leibovici Leonard, Yahav Dafna, Paul Mical · Clin Infect Dis · 2010
PMID: 21050112Meta-Analysis
Efficacy and safety of cefepime: a systematic review and meta-analysis.
Yahav Dafna, Paul Mical, Fraser Abigail et al. · Lancet Infect Dis · 2007
PMID: 17448937Meta-Analysis
Bronchopulmonary disposition of IV cefepime/taniborbactam (2-0.5 g) administered over 2 h in healthy adult subjects.
Asempa Tomefa E, Kuti Joseph L, Nascimento Jeffrey C et al. · J Antimicrob Chemother · 2023
PMID: 36617636RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Cefepime (substance)
SNOMED CT
96048006
UMLS CUI
C0055003
RxNorm CUI
20481

Clinical Data

This intervention maps to 17 entities in the Healos knowledge graph.

17
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
8
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.